Lepu Medical
VC Fund
Changping, China
Lepu Medical is a VC fund in Changping focused on Health Care and Artificial Intelligence. Lepu Medical Technology (Beijing) Co., Ltd. was established in 1999. It is specialized in developing, manufacturing and marketing the high-tech medical devices and equipment. Today, Lepu Medical has grown into a global leading group company in the fields of cardiovascular interventions, structural heart diseases, cardiac rhythm management,anesthesia and critical care, in vitro diagnostics and general surgery with products include coronary stents, dilatation balloon catheters, interventional accessories, occlusion devices, mechanical heart valves, electrophysiology catheters, pacemakers, in vitro diagnostic equipment and biomarkers, DSA systems and surgical staplers. In 2009, Lepu Medical successfully went public, and listed on ChiNext Shenzhen Stock Exchange Market (stock code: 300003).
- Total investments:
- 8
- Last investment:
- Lead investor:
- 38%
Last updated:
For AI agents: llms.txt
Industries Lepu Medical invests in
Stages Lepu Medical invests in
Countries Lepu Medical invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Zhongjie Pu
|
|||
4 more contacts available
Investment Focus
Industry
- Health Care 4 (50%)
- Artificial Intelligence 3 (38%)
- Medical 2 (25%)
- Biotechnology 2 (25%)
- Medical Device 2 (25%)
Stage
- Series A 3 (38%)
- Series C 3 (38%)
- Angel 1 (13%)
- Series D 1 (13%)
Country
- China 6 (75%)
- United States 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Zhongjie Pu
Chairman & CEO
|
Chairman & CEO | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
Silicon Core
|
Silicon Core specializes on massive code models, AI-powered programming robots, and corporate private deployment. | Angel / Jul 07, 2026 | |
Shenda Endoscope
|
Shenda Endoscope develops and manufactures medical rigid endoscopes that use French optical materials and optical fiber to ensure the performance and quality of endoscopes. | Series C / Jul 20, 2023 | |
Guizhou Yizhiying Technology
|
Guizhou Yizhiying Technology is an enterprise specializing in the field of artificial intelligence medical treatment. It intelligently analyzes medical image big data as it relies on self-developed core technologies of deep learning and medical image analysis. | Series A / Jan 18, 2023 | |
Inspirna
|
Inspirna (formerly Rgenix) is a clinical-stage biopharmaceutical company developing first-in-class/best-in-class drug candidates that target critical cancer drivers. Our discovery platform leverages RNA biology to discover novel RNA dysregulated cancer drivers that can be targeted by small molecules and biologics. Clinical programs arefirst-in-class oral small molecules in development for patients with RAS mutant CRC (RGX-202; Phase 1b) as well as SCLC and NSCLC (RGX-104; Phase 1b/2) | $55.1M / Series D / Jul 11, 2022 | |
Lepu Bio
|
Lepu Bio is a biotech company that develops a tumor immunology technology. It has established an industrial platform for target discovery, drug discovery, development, and production. The company's core products, PD-1, PD-L1, oncolytic virus, and multiple ADC products, have entered the clinical stage I-III. | $127.6M / Series A / Jul 02, 2019 | |
24tidy
|
Thai flute rookie network as the Internet industry, providing people with more clean living, so you every day: clean as new!Thai flute network using advanced Internet technology, the use of the washing plant type, to provide users with fast, convenient and high-quality cleaning services.Whether it is in the Thai flute net tops, culottes, orshoes, bags, leather, or home sofa cushion, carpet, or car seat, and we stop to help you clean and care as new. | $30M / Series C / Nov 29, 2018 | |
|
Inspirna
|
Inspirna (formerly Rgenix) is a clinical-stage biopharmaceutical company developing first-in-class/best-in-class drug candidates that target critical cancer drivers. Our discovery platform leverages RNA biology to discover novel RNA dysregulated cancer drivers that can be targeted by small molecules and biologics. Clinical programs arefirst-in-class oral small molecules in development for patients with RAS mutant CRC (RGX-202; Phase 1b) as well as SCLC and NSCLC (RGX-104; Phase 1b/2) | $40M / Series C / Oct 09, 2018 | |
Youjiali
|
Youjiali is a mobile ECG medical equipment and artificial intelligence ECG assisted analysis technology. | $1.4M / Series A / Oct 09, 2015 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Lepu Medical invest in?
Lepu Medical invests primarily in Health Care, Artificial Intelligence and Medical startups, most often at Series A and Series C stage. Most of the 8 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Lepu Medical?
Public channels for Lepu Medical include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Lepu Medical?
The team at Lepu Medical includes Zhongjie Pu (Chairman & CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
